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408Objective: Improvement of vein graft patency may be highly beneficial in coronary artery bypass grafting, but
graft degeneration is considered to be one of the main pathophysiologic causes for vein graft failure. Because
peroxisome proliferator-activated receptor-g activator pioglitazone was recently reported to possess pleiotropic
protective effects on various organs and tissues, we conducted experiments to test the hypothesis that pioglitazone
could prevent graft degeneration, leading to the preservation of vein graft integrity.
Methods: In a rat aortic interposition model with autologous femoral vein, pioglitazone (3 mg/kg/d) or vehicle
(normal saline) was given to rats by gastric gavage once per day beginning 3 days before surgery and ending 8
weeks after surgery. Vein graft degeneration and remodeling were assessed at 24 hours, 7 days, 8 weeks, and 6
months after surgery.
Results: At 24 hours, pioglitazone significantly reduced endothelial desquamation, reactive oxygen species gen-
eration, myeloperoxidase activity, and lipid peroxidation in vein grafts. At 7 days, mRNA expression and gelat-
inolytic activity of matrix metalloproteinase-2 and 9 in vein grafts were significantly suppressed by pioglitazone
treatment. Immunofluorescent staining showed that pioglitazone enhanced peroxisome proliferator-activated re-
ceptor-g expression in vein grafts at 8 weeks, especially in their intimal side. At 6 months, pioglitazone treatment
prevented graft dilation (52.3%  3.1% vs 90.7%  9.9%, P ¼ .0041) and neointimal hyperplasia (14.6%
 1.3% vs 29.9%  2.9%, P ¼ .0008), and increased graft flow velocity ratio (0.86  0.03 vs 0.59  0.04,
P< .0001), compared with vehicle treatment.
Conclusion: Pioglitazone prevents graft degeneration under arterial pressure stress and preserves the vein graft
integrity in a rat aortic interposition model. (J Thorac Cardiovasc Surg 2010;140:408-16)Supplemental material is available online.
Although the clinical use of arterial conduits, such as the in-
ternal thoracic artery or radial artery, is a current trend in cor-
onary artery bypass grafting (CABG) because of its superior
long-term patency, the saphenous vein is still widely used as
the bypass conduit. After grafting, the vein grafts are imme-
diately exposed to arterial pressure and pulsatile blood flow,
thereby increasing wall tension and shear forces. These he-
modynamic changes and physiologic stresses lead to graft
overdistention, endothelial damage, and dysfunction, and in-
volve proliferation and migration of smooth muscle cells
(SMCs) into the vein graft. Eventually, the vein grafts mighte Department of Surgery, Division of Cardiovascular Surgery, Kobe Univer-
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The Journal of Thoracic and Cardiovascular Surgundergo vascular remodeling, including neointimal hyper-
plasia, which is considered to be one of the major causes
of vein graft failure.1,2
Thiazolidinediones, which include the presently available
drug pioglitazone, are well established insulin-sensitizing
agents that act as agonists of the ligand-activated transcrip-
tional factor peroxisome proliferator-activated receptor
(PPAR)-g.3 It was recently reported that pioglitazone
possesses pleiotropic cardiovascular protective actions in
experimental settings, including anti-inflammatory and anti-
proliferative properties.4,5 Migration and proliferation of
vascular SMCs are inhibited by pioglitazone,6 and pioglita-
zone reduces hypertensive vascular injury and hypertro-
phy.7,8 However, there is no report to elucidate an efficacy
of pioglitazone on vein grafts in the arterial environment.
This study evaluates whether pioglitazone has the poten-
tial to preserve vein graft integrity in the arterial environment
associated with preventing graft distension and intimal
hyperplasia.
MATERIALS AND METHODS
Animals
Sixty male Sprague-Dawley rats weighing 450 to 550 g (10 weeks of
age, CLEA Japan Inc, Tokyo, Japan) were used in the present study. The
handling of laboratory animals and their use in experiments conformed to
the Guidelines for Animal Experiment at Kobe University Graduate Schoolery c August 2010
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
MMP ¼ matrix metalloproteinase
PPAR ¼ peroxisome proliferator-activated receptor
SMA ¼ smooth muscle actin
SMC ¼ smooth muscle cell
TIMP ¼ tissue inhibitor of matrix
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Sof Medicine (permission number: P080120) and the Guide for the Care and
Use of Laboratory Animals (www.nap.edu/catalog/5140.html).
Drug Treatment
Pioglitazone, provided by Takeda Chemical Industries (Tokyo, Japan),
was diluted in normal saline. Pioglitazone (3 mg/kg/d)9,10 or vehicle (nor-
mal saline) was given to rats by gastric gavage once per day beginning 3
days before surgery and ending 8 weeks after surgery.
Rat Aortic Bypass Model
Rats were placed in a closed chamber containing diethyl ether (Wako,
Osaka, Japan). After loss of consciousness, the rats were weighed and anes-
thetized with pentobarbiturate (5 mg/kg, intraperitoneally). The anesthe-
tized rats were placed under a Leica M651 operating microscope (Leica
Microsystems, Heerbrugg, Switzerland) with 63 to 103 magnification.
The right femoral vein was harvested and rinsed in heparinized saline.
The infrarenal abdominal aorta was transected and interposed with the au-
tologous femoral vein graft (1.0 cm in length) by end-to-end anastomosis
with a continuous running suture of 8-0 polypropylene (PROLENE; John-
son & Johnson Gateway, LLC, Piscataway, NJ). The right femoral vein was
not reconstructed. After the anastomosis, graft patency was evaluated by
direct visualization before layered surgical closure. The surgeon (Z.C.)
was blinded to treatment group in the present study. A 1-week postoperative
prophylactic antibiotic regimen was followed for all rats. Their body weight
was measured once per week. For monitoring pioglitazone-related adverse
effects, the rats were observed every day postoperatively.
Study Design
The present study design is shown in Figure E1. The end points of the
present study were 24 hours, 7 days, 8 weeks, and 6 months after surgery
in each group. The experiments of 7-day, 8-week, and 6-month end points
were performed on 6 rats per each group. The 24-hour experiment was per-
formed in 2 subsets of each group, which provided samples for Evans blue
assay (n ¼ 6 in each group) and other assays (n ¼ 6 in each group). The
7-day samples were used for matrix metalloproteinase (MMP) analysis,
and the 8-week and 6-month samples were used for physiologic, morpho-
metric, and histologic analyses.
Macroscopic Assessments
Animalswere anesthetized, and the abdominal aortawas exposed and pho-
tographedwith aLeica ICDdigital camera (LeicaMicrosystems).Graft diam-
eter was measured under physiologic conditions with an optical micrometer
by the person (A.T.) who was blinded to the different treatment groups. The
graft diameterwas defined as themaximumdimension of the transverseminor
axis of the vein graft, and the graft dilation was calculated by the following
formula according to our previous study:11 graft dilation ratio (%) ¼ (diam-
eter at harvestingdiameter at implantation)/diameter at implantation3 100.
The velocity of blood flow through the vein graft was measured using
a Transonic flowmeter (3 mm in size of the probe; Transonic System Inc,The Journal of Thoracic and CaNewYork, NY) and recorded with PowerLab/MacLab800 (AD Instruments
Japan Inc, Nagoya, Japan). It was measured at the proximal aorta, vein graft,
and distal aorta, and the mean value was taken as the flow velocity. The graft
flow velocity ratio was calculated according to the following formula: graft
flow velocity ratio ¼ graft flow velocity/proximal aorta flow velocity.
Histology
Harvested tissues were rinsed in saline and fixed in 10% formalin. The
formalin-fixed samples were dehydrated in a graded ethanol bath, cleaned in
xylene, and embedded in paraffin. Sections (5 mm thick) were stained by he-
matoxylin–eosin and Elastica vonGieson. After those images were captured
using a microscopic system (BZ-8100, KEYENCE Co, Osaka, Japan), his-
tologic analyses of the sections were performed using ImageJ version 1.41
software (National Institutes of Health, Bethesda, Md). The neointimal
thickness at the anastomosis site was calculated by converting the number
of pixels to micrometers using a stage micrometer on the captured images,
and the neointimal hyperplasia at the aneurysmal site was calculated by us-
ing the following formula:11 neointimal hyperplasia (%)¼ neointimal area/
area bounded by the media 3 100.
Immunohistochemical Staining
Immunohistochemical staining was performed on the paraffin-embedded
section by using ENVISION kit/HRP (DAKO, Kyoto, Japan) with primary
antibody, anti-humana-smoothmuscle actin (aSMA)/horseradishperoxidase
(DAKO). Diaminobenzidine substrate (DAKO) was used as a chromogen,
and cell nuclei were counterstained with hematoxylin. The aSMA-positive
area in a cross-section was semiquantified using the ImageJ software and
calculated by dividing the aSMA-positive area by the cross-sectional vein
graft area.
Immunofluorescent Staining
Immunofluorescent staining was performed on the paraffin-embedded
section with primary antibody, mouse monoclonal anti-PPAR-g antibody
(Santa Cruz Biotechnology, Santa Cruz, Calif). Fluorescein-linked sheep
anti-mouse antibody was used as secondary antibody (Amersham Biosci-
ences, Buckinghamshire, UK). The cell nuclei were counterstained with
40,6-diamidino-2-phenylindole (Chemicon International, Temecula, Calif).
Evans Blue Staining
To evaluate the endothelial desquamation in the whole area of the vein
graft at 24 hours after surgery, Evans blue staining was performed as
described previously with some modifications.11,12 Briefly, Evans blue
(10mg/kg; Sigma-Aldrich, St Louis,Mo)was injected intravenously 2 hours
before vein graft harvesting. After perfusion-fixation with 100% methanol,
vein grafts including both proximal and distal anastomotic sites were har-
vested and opened longitudinally for macroscopic examination. After the
vein graft was separated from aorta, its uptake of Evans blue was quantified
by formamide extraction (55C for 2 hours) measuring absorbance at
595 nm. The concentration was determined by the calibration curve, and
the data were standardized to the protein concentration of each sample as
determined by a micro BCA protein assay kit (Pierce, Rockford, Ill).
Myeloperoxidase Assay
MPO activity in vein grafts at 24 hours after surgery was assessed as pre-
viously described.12 MPO values were standardized to the protein concen-
tration of each sample. Data are expressed as the change in absorbance at
450 nm/min/mg of total protein.
Lipid Peroxidation Assay
Lipid peroxidation in vein grafts at 24 hours after surgery was assessed
using spectrophotometric assay for malondialdehyde (BIOXYTECHMDA-
586; OXIS International Inc, Foster City, Calif), according to the manufac-
turer’s instructions. Data are standardized by protein concentration.rdiovascular Surgery c Volume 140, Number 2 409
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FIGURE 1. Effects of pioglitazone on endothelial desquamation and oxidative stress in vein grafts at 24 hours. A, In vivo Evans blue staining of vein grafts.
Anastomotic sites (arrows). Bar ¼ 5 mm. B, In situ detection of superoxide generation (red fluorescence). Bar ¼ 100 mm. C, Malondialdehyde levels as an
indicator of lipid peroxidation. D, MPO activity. DAbs, change in absorbance. *P<.05. All data are expressed as mean standard error of the mean (SEM)
for n ¼ 6 per group. MDA, Malondialdehyde.
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Analysis
Total RNA was isolated from graft samples using an RNeasy fibrous tis-
sue mini-kit (Qiagen, Venlo, The Netherlands) according to the manufac-
turer’s instructions. The RNA was transcribed and amplified to cDNA
using a high-capacity cDNA reverse transcription kit (Applied Biosystems,
Foster City, Calif). Quantitative real-time polymerase chain reaction analy-
sis for mRNA of MMP-2, MMP-9, tissue inhibitor of MMP (TIMP)-1, and
TIMP-2 was performed using the ABI Prism 7500 sequence detector system
(Applied Biosystems) with TaqMan universal polymerase chain reaction410 The Journal of Thoracic and Cardiovascular Surgmaster mix and TaqMan real-time polymerase chain reaction primers
(Applied Biosystems). The expression level of each mRNA was divided
by the mRNA level of the housekeeping gene glyceraldehyde-3-phosphate
dehydrogenase.
Gelatin Zymography
Proteins of graft samples were extracted using a buffer containing
50 mmol/L Tris-HCl (pH 7.5), 150 mmol/L NaCl, 1% Triton X-100,
0.2% sodium dodecyl sulfate, and 1 mmol/L EDTA, supplemented with
protease inhibitors (20 mg/mL aprotinin, 10 mg/mL leupeptin, andery c August 2010
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FIGURE 2. Protease activity and mRNA expression in vein grafts at 7 days. A, mRNA expression of MMP-2, MMP-9, TIMP-1, and TIMP-2. B, Gelati-
nolytic activities of MMP-2 and MMP-9 by gelatin zymography, and their densitometric analysis. *P<.05. All data are expressed as mean SEM for n¼ 6
per group. Pio, Pioglitazone; NS, not significant; MMP, matrix metalloproteinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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ities of MMP-2 and MMP-9 in vein grafts, the gelatin-zymography kit (Pri-
mary Cell Co, Hokkaido, Japan) was used according to the manufacturer’s
instructions. After the protein concentration was standardized, 20 mg of pro-
tein was applied in each lane to the electrophoresis. Densitometric analysis
of lytic bands for MMP-2 and MMP-9 was performed by ImageJ version
1.41.
Statistics
Database management and statistical analysis were performed with Stat-
view Software Version 5.0 (SAS Institute Inc, Cary, NC). All values are ex-
pressed as mean  standard error of the mean. Statistical analyses of data
were performed by unpaired Student t test or 1-way analysis of variance
by the Bonferroni post hoc test, as appropriate.
RESULTS
The surgical ischemic time during an end-to-end interpo-
sition of the vein graft was approximately 20 minutes in bothThe Journal of Thoracic and Cathe pioglitazone and control groups. There was no signifi-
cant difference in the ischemic time between the 2 groups.
There was neither technical failure nor death intraopera-
tively, and all animals have uneventfully survived until
each end point. No thrombus formation in vein grafts was
observed postoperatively. During the postoperative observa-
tion, there were no significant differences of body weight
change or histologic findings of heart, lung, liver, and kidney
between the pioglitazone and control groups postopera-
tively.
Preservation of Endothelial Function
To evaluate endothelial desquamation of vein grafts
caused by exposure to the arterial environment, the grafts
were stained with Evans blue dye, which is believed to pen-
etrate intimal areas that were not covered by endothelium.11rdiovascular Surgery c Volume 140, Number 2 411
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FIGURE 3. Graft flow velocity in vein grafts. A, Blood flowwaveforms in
proximal aorta, vein graft, and distal aorta at 6 months. B, Graft flow veloc-
ity ratio at 8 weeks and 6 months. *P<.05 by analysis of variance. All data
are expressed as mean  SEM for n ¼ 6 per group. Ao, Aorta.
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were stained more deeply with Evans blue than those in pio-
glitazone treatment. Quantitatively, the uptake of Evans blue
in vein grafts was significantly less in the pioglitazone group
compared with the control group (29.1  2.5 mg/mg protein
vs 45.6  2.8 mg/mg protein, P ¼ .0003; Figure 1, A). Be-
cause the arterial pressure stretch of vein grafts would induce
a generation of reactive oxygen species and oxidative
injury,13,14 we next evaluated oxidative stress in vein grafts
at 24 hours. The intensity of red oxidative fluorescence in the
pioglitazone group was apparently lower than in the control
group (Figure 1, B). The graft oxidative damage, quantified
by malondialdehyde levels in vein grafts, was significantly
reduced by pioglitazone treatment compared with the
control treatment (25  13 pmol/mg protein vs 85  14
pmol/mg protein, P ¼ .0104; Figure 1, C). MPO activity
in the pioglitazone group was also significantly less than
in the control group (0.06  0.01 DAb/min/mg vs
0.29  0.05 DAb/min/mg protein, P ¼ .0009; Figure 1, D).
Suppression of Matrix Metalloproteinase
The arterial pressure stretch of vein grafts also enhances
the activity of MMPs, which are especially important regu-
lators of vein graft architecture because of their specificity
for elastin.15 At 7 days after surgery in the present study,
the MMP-2 and MMP-9 mRNA expressions were signifi-
cantly down-regulated by pioglitazone treatment compared
with control treatment (MMP-2, 0.97  0.12 vs 1.53 
0.18, P ¼ .0254; MMP-9, 0.46  0.06 vs 0.83  0.05, P
¼ .0004; Figure 2, A). Gelatinolytic activities of MMP-2
andMMP-9 proteins were also significantly lower in the pio-
glitazone group than in the control group (MMP-2, 47.4 
2.6 vs 74.6  8.4, P ¼ .0113; MMP-9, 20.9  1.7 vs 33.0
 2.5, P ¼ .0023; Figure 2, B). Because the MMP activities
are tightly regulated by TIMPs,15 we also evaluated mRNA
expression of TIMP-1 and TIMP-2 in vein grafts. However,
there were no significant differences in these mRNA
expressions between the pioglitazone and control groups
(Figure 2, A).
Maintenance of Graft Blood Flow Velocity
There was no significant difference in mean graft blood
flow velocity immediately after surgery between the groups.
Although the graft flow velocity ratio gradually decreased
after surgery, it was significantly higher in the pioglitazone
group than in the control group at both 8 weeks and 6months
after surgery (8 weeks, 0.87  0.02 vs 0.66  0.05; 6
months, 0.86  0.03 vs 0.59  0.04, P< .0001 by analysis
of variance; Figure 3).
Prevention of Graft Dilation
Graft dilation was observed under physiologic conditions
at 8 weeks and 6 months. At both 8 weeks and 6 months, the
graft dilation ratios were significantly lower in the pioglita-412 The Journal of Thoracic and Cardiovascular Surgzone group than in the control group (8 weeks, 36.3% 
2.2% vs 61.4%  3.9%, P ¼ .0002; 6 months, 52.3% 
3.1% vs 90.7%  9.9%, P ¼ .0041; Figure 4, A)
Enhancement of Peroxisome Proliferator-Activated
Receptor-g Expression
Immunofluorescent staining has shown that pioglitazone
treatment up-regulates PPAR-g expression in vein grafts at
8 weeks after surgery compared with the control (Figure 4,
B). There was especially a stronger enhancement of
PPAR-g expression in the intimal side of grafts than in the
adventitial side by pioglitazone.
Reduction of Neointimal Hyperplasia
At 6 months, neointimal hyperplasia and SMC prolifera-
tion in vein grafts were assessed by Elastica von Gieson
staining and aSMA immunostaining, respectively (Figure 5,
A, B). Pioglitazone treatment reduced both neointimal hy-
perplasia and aSMA-positive area significantly compared
with the control group (neointimal hyperplasia: 14.6% 
1.3% vs 29.9%  2.9%, P ¼ .0008; aSMA-positive
area: 27.7%  2.0% vs 47.6%  3.6%, P ¼ .0007). At
the anastomosis site of vein grafts, neointimal thickness
was also significantly thinner in the pioglitazone group
than in the control group (67.6  2.1 mm vs 134.6 
19.6 mm, P ¼ .0069; Figure 5, C).ery c August 2010
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It is well recognized that inevitable exposure of vein grafts
to the arterial system with high pressure and pulsatility con-
tributes to their circumferential stretch. It leads to structural
and functional changes in the graft wall, which is known as
vascular remodeling. We have first described that pioglita-
zone can regulate the distended vascular remodeling of
vein graft, likely as the result of PPAR-g up-regulation.
The main findings of this study are that pioglitazone treat-
ment can (1) prevent acute graft damage caused by both me-
chanical and oxidative stresses, (2) regulate the extracellular
matrix integrity by suppressing MMP-2 and MMP-9 activi-
ties, (3) inhibit the graft dilation and maintenance of the graft
flow velocity, and (4) reduce neointimal hyperplasia with
less SMC proliferation in vein grafts.
It is not surprising that pioglitazone enhances PPAR-g ex-
pression in vein grafts. Previous experimental studies have
demonstrated that PPAR-g activation with thiazolidine-
diones has protective effects against hypertensive vascular
injury and hypertrophy.7,8 Notably, treatment with PPAR-g
agonists, such as pioglitazone and rosiglitazone, reduces
aortic aneurysmal formation in mice.16,17 Therefore, there
would be obvious potential benefits of vein graft protectionThe Journal of Thoracic and Cainduced by PPAR-g activation with pioglitazone. In the
present study, the enhancement of PPAR-g expression
was clearly observed in the intimal side of vein grafts, pos-
sibly because of a direct pharmacologic effect of pioglita-
zone carried through the bloodstream. Although
pioglitazone has some clinical drawbacks, such as causing
fluid retention and congestive heart failure, we believe that
pioglitazone has numerous advantages as long as the dose
is optimal. In accordance with the previous report,9,10 we ad-
ministered the same dosage (3 mg/kg/d) of pioglitazone in
this study without those adverse effects.
Circumferential pressure stretch of the vein graft is be-
lieved to contribute to the degradation of its endothelium.
The average circumferential pressure stress in the vein graft
can be increased by 140 times or greater compared with that
in a native vein.2 Liu and colleagues18 reported that vein
grafts exposed to arterial pressure lost up to 60% of the en-
dothelial cells and SMCs within 12 hours after surgery. Our
previous study also demonstrated that the endothelium of
vein grafts was desquamated and that the media disrupted
at 24 hours after surgery.11 In the present study, the endothe-
lial desquamation of vein graft, which was evaluated with
Evan’s blue staining, was significantly reduced byrdiovascular Surgery c Volume 140, Number 2 413
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FIGURE 5. Histologic findings in vein grafts at 6 months. A, Elastin von Gieson staining and aSMA immunostaining. Bar¼ 500 mm. B, Area of neointimal
hyperplasia and aSMA-positive area. C, Neointimal thickness at anastomosis site (hematoxylin–eosin staining). Bar ¼ 200 mm. *P< .05. All data are
expressed as mean  SEM for n ¼ 6 per group. EVG, Elastin von Gieson; SMA, smooth muscle actin.
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endothelial damage in vein grafts induced a generation of
reactive oxygen species and an activation of early inflamma-
tion.19 Reactive oxygen species were produced by all vascu-
lar cells, including endothelial cells, SMCs, and infiltrated
leukocytes. Increased superoxide generation was observed
in the vein grafts by dihydroethidium staining in the present
study. Pioglitazone treatment effectively attenuated the
superoxide generation. Moreover, both MPO activity as
a producer of leukocytic activity and lipid peroxidation as
an indicator of oxidative lipid damage in vein grafts were
also significantly suppressed by pioglitazone. Because414 The Journal of Thoracic and Cardiovascular Surgoxidative stress including lipid peroxidation has been impli-
cated in the initiation and progression of vein graft failure,13
these results suggest the subsequent vein graft failure.
The activities of extracellular matrix-degrading MMPs,
which are important regulators of vein graft architecture,15
have a strongmechanistic link to radical oxygen species gen-
eration in vascular aneurysm formation.20 In addition, the up-
regulation of MMPs, especially MMP-2 and MMP-9, have
been shown to induce SMC proliferation andmigration lead-
ing to neointimal formation in vein grafts.15 The present
study demonstrated that pioglitazone treatment down-
regulated MMP-2 and MMP-9 expressions and activities atery c August 2010
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lated by TIMPs,15 pioglitazone did not affect significant
changes of TIMP-1 and TIMP-2 mRNA expression in vein
grafts. These results suggest that pioglitazone can regulate
the extracellular matrix integrity by suppressing MMP-2
and MMP-9, eventually resulting in the regulation of vein
graft remodeling, such as dilation and neointimal formation.
Poiseuille’s law defines that increasing diameter in ves-
sels induces a decrease of flow velocity with low shear
stress. The present study showed distinct circumferential di-
lation with low flow velocity after vein grafting. Pioglita-
zone treatment significantly suppressed the graft dilation
and maintained the graft flow velocity possibly with good
shear stress. In addition, both high circumferential pressure
stress and low shear stress are the main triggers for the devel-
opment of neointimal hyperplasia in vein grafts, associated
with subsequent SMC proliferation.2,21 The present study
showed that pioglitazone treatment significantly suppressed
SMC proliferation and neointimal hyperplasia at the aneu-
rysmal site and the anastomosis site of vein grafts. These re-
sults suggest that pioglitazone could preserve vein graft
integrity and regulate its remodeling in the chronic phase.
Although the mechanism of preservation of the vein graft in-
tegrity was not elucidated in the present study, Duan and col-
leagues22 currently reviewed the effects of PPAR-g in the
vasculature and showed that PPAR-g activation inhibits
SMC proliferation and migration, as well as endothelial in-
flammation. They introduced several mechanisms of the in-
hibitory effect on SMC proliferation in their review, and one
of the interesting mechanisms is that the suppression of ROS
production via PPAR-g activation contributes to the inhibi-
tion of SMC proliferation and migration via an inhibition on
telomerase activity or MMP-9 activity. Further studies are
needed to elucidate the mechanism of preservation of the
vein graft integrity by pioglitazone.
Study Limitations
This study has some limitations that deserve attention.
There is some discrepancy between the rat aortic interposi-
tion model and clinical CABG, with regard to species, het-
erotopic grafting, grafting technique, and physiologic
hemodynamics. The present study has not established the
dose-response relation of pioglitazone to a preservation of
the vein graft integrity. Although other doses or dosing reg-
imens of pioglitazone were not applied in the present study,
previous studies have demonstrated that plasma pioglitazone
concentration in the animals treated with 3 mg/kg/d is within
the range achieved in humans after oral administration of its
clinical dosage (30 mg/d).9,23 Current studies have shown
that pioglitazone prevented reactive hypoglycemia in pa-
tients with an impaired glucose tolerance24 and improved
coronary endothelial function without any change in blood
glucose, insulin, or hemoglobin-A1c levels in nondiabetic
patients with coronary artery disease.25 Although adverseThe Journal of Thoracic and Caeffects of pioglitazone were not observed in the present
study, the use of pioglitazone in the patients who underwent
CABG, particularly those with congestive heart failure and
cardiomyopathies, might be the high incidence of fluid re-
tention associated with its use. Further studies of pioglita-
zone for the vein graft integrity preservation, including
clinical trials, are needed.
CONCLUSIONS
Pioglitazone treatment prevents graft dilation and neointi-
mal hyperplasia, which leads to preservation of the vein graft
integrity in a rat aortic interposition model. Pioglitazone has
a potential use for post-CABG regimens by providing an im-
provement of the long-term patency of the vein grafts. Fur-
ther investigation will be required to determine if this will
hold true in a clinical setting.
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FIGURE E1. Schematic representation of the present study design. Drug
treatment (pioglitazone or vehicle) was provided to rats by gastric gavage
once per day beginning 3 days before operation and ending 8 weeks after
operation. The end points of the present study were 24 hours, 7 days,
8 weeks, and 6 months after operation. Op, Operation.
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